Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Harvard Business School
AstraZeneca
Farmers Insurance
Moodys
Argus Health

Generated: May 20, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,659,282

« Back to Dashboard

Which drugs does patent 7,659,282 protect, and when does it expire?

Patent 7,659,282 protects NUEDEXTA and is included in one NDA.

This patent has sixty-seven patent family members in twenty-one countries.

Summary for Patent: 7,659,282
Title:Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
Abstract:Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine.
Inventor(s): Yakatan; Gerald (Del Mar, CA), Berg; James (San Diego, CA), Pope; Laura E. (Carlsbad, CA), Smith; Richard A. (La Jolla, CA)
Assignee: Avanir Pharmaceuticals, Inc. (Aliso Viejo, CA)
Application Number:11/035,213
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,659,282
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,659,282
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,659,282

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Avanir Pharms NUEDEXTA dextromethorphan hydrobromide; quinidine sulfate CAPSULE;ORAL 021879-001 Oct 29, 2010 AB RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF PSEUDOBULBAR AFFECT ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 7,659,282

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 399553 ➤ Sign Up
Australia 2003251971 ➤ Sign Up
Australia 2008201775 ➤ Sign Up
Australia 2010212348 ➤ Sign Up
Australia 2013202184 ➤ Sign Up
Australia 2013202187 ➤ Sign Up
Australia 2015203262 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Accenture
Queensland Health
QuintilesIMS
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.